You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameEfavirenz
Accession NumberDB00625  (APRD00059, DB07709)
TypeSmall Molecule
GroupsApproved, Investigational
DescriptionEfavirenz (brand names Sustiva® and Stocrin®) is a non-nucleoside reverse transcriptase inhibitor (NNRTI) and is used as part of highly active antiretroviral therapy (HAART) for the treatment of a human immunodeficiency virus (HIV) type 1. For HIV infection that has not previously been treated, efavirenz and lamivudine in combination with zidovudine or tenofovir is the preferred NNRTI-based regimen. Efavirenz is also used in combination with other antiretroviral agents as part of an expanded postexposure prophylaxis regimen to prevent HIV transmission for those exposed to materials associated with a high risk for HIV transmission.
Structure
Thumb
Synonyms
(-)-6-CHLORO-4-cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-2H-3,1-benzoxazin-2-one
(S)-6-chloro-4-(Cyclopropylethynyl)-1,4-dihydro-4-(trifluoromethyl)-2H-3,1-benzoxazin-2-one
(S)-6-chloro-4-Cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-benzo[D][1,3]oxazin-2-one
6-chloro-4-(2-Cyclopropyl-1-ethynyl)-4-trifluoromethyl-(4S)-1,4-dihydro-2H-benzo[D][1,3]oxazin-2-one
Efavirenz
Éfavirenz
Efavirenzum
External Identifiers
  • DMP 266
  • L 743726
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Auro-efavirenzTablet600 mgOralAuro Pharma Inc2014-03-03Not applicableCanada
Mylan-efavirenzTablet600 mgOralMylan Pharmaceuticals Ulc2013-07-30Not applicableCanada
StocrinTablet, film coated200 mgOralMerck Sharp & Dohme Ltd.1999-05-28Not applicableEu
StocrinCapsule200 mgOralMerck Sharp & Dohme Ltd.1999-05-28Not applicableEu
StocrinCapsule50 mgOralMerck Sharp & Dohme Ltd.1999-05-28Not applicableEu
StocrinSolution30 mg/mlOralMerck Sharp & Dohme Ltd.1999-05-28Not applicableEu
StocrinCapsule100 mgOralMerck Sharp & Dohme Ltd.1999-05-28Not applicableEu
StocrinTablet, film coated600 mgOralMerck Sharp & Dohme Ltd.1999-05-28Not applicableEu
StocrinCapsule200 mgOralMerck Sharp & Dohme Ltd.1999-05-28Not applicableEu
StocrinTablet, film coated50 mgOralMerck Sharp & Dohme Ltd.1999-05-28Not applicableEu
SustivaTablet, film coated600 mgOralBristol Myers Squibb Pharma Eeig1999-05-28Not applicableEu
SustivaTablet, film coated600 mg/1OralPhysicians Total Care, Inc.2012-10-11Not applicableUs
SustivaTablet, film coated600 mg/1OralREMEDYREPACK INC.2016-03-31Not applicableUs
SustivaCapsule200 mgOralBristol Myers Squibb Pharma Eeig1999-05-28Not applicableEu
SustivaCapsule, gelatin coated50 mg/1OralBristol Myers Squibb Pharma Company1998-09-17Not applicableUs
SustivaCapsule50 mgOralBristol Myers Squibb Pharma Eeig1999-05-28Not applicableEu
SustivaTablet, film coated600 mg/1OralA S Medication Solutions2002-01-02Not applicableUs
SustivaTablet, film coated600 mgOralBristol Myers Squibb Pharma Eeig1999-05-28Not applicableEu
SustivaCapsule, gelatin coated200 mg/1OralBristol Myers Squibb Pharma Company1998-09-17Not applicableUs
SustivaCapsule100 mgOralBristol Myers Squibb Pharma Eeig1999-05-28Not applicableEu
SustivaTablet, film coated600 mgOralBristol Myers Squibb Pharma Eeig1999-05-28Not applicableEu
SustivaTablet, film coated600 mg/1OralBristol Myers Squibb Pharma Company2002-01-02Not applicableUs
SustivaCapsule200 mgOralBristol Myers Squibb Pharma Eeig1999-05-28Not applicableEu
Sustiva 100mgCapsule100 mgOralBristol Myers Squibb Canada1999-03-252008-03-27Canada
Sustiva 200mgCapsule200 mgOralBristol Myers Squibb Canada1999-03-25Not applicableCanada
Sustiva 50mgCapsule50 mgOralBristol Myers Squibb Canada1999-03-25Not applicableCanada
Sustiva TabletsTablet600 mgOralBristol Myers Squibb Canada2002-11-05Not applicableCanada
Teva-efavirenzTablet600 mgOralTeva Canada Limited2013-07-30Not applicableCanada
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
E.FMcNeil & Argus
EfavirCipla
EfavirenzAspen Pharmacare
EfcureEmcure Pharmaceuticals
EffervenRanbaxy Laboratories
EstivaHetero
EvirenzAlkem Laboratories
StocrinMerck & Co.
ViranzAurobindo Pharma
Brand mixtures
NameLabellerIngredients
AtriplaLake Erie Medical DBA Quality Care Products LLC
SaltsNot Available
Categories
UNIIJE6H2O27P8
CAS number154598-52-4
WeightAverage: 315.675
Monoisotopic: 315.027390859
Chemical FormulaC14H9ClF3NO2
InChI KeyXPOQHMRABVBWPR-ZDUSSCGKSA-N
InChI
InChI=1S/C14H9ClF3NO2/c15-9-3-4-11-10(7-9)13(14(16,17)18,21-12(20)19-11)6-5-8-1-2-8/h3-4,7-8H,1-2H2,(H,19,20)/t13-/m0/s1
IUPAC Name
(4S)-6-chloro-4-(2-cyclopropylethynyl)-4-(trifluoromethyl)-2,4-dihydro-1H-3,1-benzoxazin-2-one
SMILES
FC(F)(F)[C@]1(OC(=O)NC2=C1C=C(Cl)C=C2)C#CC1CC1
Pharmacology
IndicationFor use in combination treatment of HIV infection (AIDS)
Structured Indications
PharmacodynamicsEfavirenz (dideoxyinosine, ddI) is an oral non-nucleoside reverse transcriptase inhibitor (NNRTI). It is a synthetic purine derivative and, similar to zidovudine, zalcitabine, and stavudine. Efavirenz was originally approved specifically for the treatment of HIV infections in patients who failed therapy with zidovudine. Currently, the CDC recommends that Efavirenz be given as part of a three-drug regimen that includes another nucleoside reverse transcriptase inhibitor (e.g., lamivudine, stavudine, zidovudine) and a protease inhibitor or efavirenz when treating HIV infection.
Mechanism of actionSimilar to zidovudine, efavirenz inhibits the activity of viral RNA-directed DNA polymerase (i.e., reverse transcriptase). Antiviral activity of efavirenz is dependent on intracellular conversion to the active triphosphorylated form. The rate of efavirenz phosphorylation varies, depending on cell type. It is believed that inhibition of reverse transcriptase interferes with the generation of DNA copies of viral RNA, which, in turn, are necessary for synthesis of new virions. Intracellular enzymes subsequently eliminate the HIV particle that previously had been uncoated, and left unprotected, during entry into the host cell. Thus, reverse transcriptase inhibitors are virustatic and do not eliminate HIV from the body. Even though human DNA polymerase is less susceptible to the pharmacologic effects of triphosphorylated efavirenz, this action may nevertheless account for some of the drug's toxicity.
TargetKindPharmacological actionActionsOrganismUniProt ID
Reverse transcriptase/RNaseHProteinyes
inhibitor
Human immunodeficiency virus 1Q72547 details
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein binding99.5-99.75%
Metabolism

Efavirenz is principally metabolized by the cytochrome P450 system to hydroxylated metabolites with subsequent glucuronidation of these hydroxylated metabolites. These metabolites are essentially inactive against HIV-1.

Route of eliminationNearly all of the urinary excretion of the radiolabeled drug was in the form of metabolites.
Half life40-55 hours
ClearanceNot Available
ToxicityNot Available
Affected organisms
  • Human Immunodeficiency Virus
Pathways
PathwayCategorySMPDB ID
Efavirenz Action PathwayDrug actionSMP00740
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
1,1,1,2 TetrafluoroethaneThe risk or severity of adverse effects can be increased when Efavirenz is combined with 1,1,1,2 Tetrafluoroethane.Investigational
7-NitroindazoleThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Efavirenz.Experimental
AbirateroneThe serum concentration of Abiraterone can be decreased when it is combined with Efavirenz.Approved
AceclofenacThe metabolism of Aceclofenac can be decreased when combined with Efavirenz.Approved
AcenocoumarolThe serum concentration of Acenocoumarol can be decreased when it is combined with Efavirenz.Approved
AcepromazineThe risk or severity of adverse effects can be increased when Acepromazine is combined with Efavirenz.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Efavirenz.Approved
AcetaminophenThe serum concentration of Acetaminophen can be decreased when it is combined with Efavirenz.Approved
Acetylsalicylic acidThe metabolism of Acetylsalicylic acid can be decreased when combined with Efavirenz.Approved, Vet Approved
AdinazolamThe serum concentration of Adinazolam can be decreased when it is combined with Efavirenz.Approved
adipiplonThe risk or severity of adverse effects can be increased when adipiplon is combined with Efavirenz.Investigational
AgomelatineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Efavirenz.Approved, Investigational
AlbendazoleThe serum concentration of Albendazole can be decreased when it is combined with Efavirenz.Approved, Vet Approved
AlclometasoneThe serum concentration of Alclometasone can be decreased when it is combined with Efavirenz.Approved
AlfaxaloneThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Efavirenz.Vet Approved
AlfentanilThe serum concentration of Alfentanil can be decreased when it is combined with Efavirenz.Approved, Illicit
AlfuzosinThe serum concentration of Alfuzosin can be decreased when it is combined with Efavirenz.Approved, Investigational
AliskirenThe serum concentration of Aliskiren can be decreased when it is combined with Efavirenz.Approved, Investigational
AllylestrenolThe serum concentration of Allylestrenol can be decreased when it is combined with Efavirenz.Approved
AlmotriptanThe serum concentration of Almotriptan can be decreased when it is combined with Efavirenz.Approved, Investigational
AlogliptinThe serum concentration of Alogliptin can be decreased when it is combined with Efavirenz.Approved
AlosetronThe serum concentration of Alosetron can be decreased when it is combined with Efavirenz.Approved, Withdrawn
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Efavirenz.Experimental, Illicit
AlprazolamThe serum concentration of Alprazolam can be decreased when it is combined with Efavirenz.Approved, Illicit, Investigational
AmbrisentanThe serum concentration of Ambrisentan can be decreased when it is combined with Efavirenz.Approved, Investigational
AmbroxolThe serum concentration of Ambroxol can be decreased when it is combined with Efavirenz.Approved
AminophenazoneThe serum concentration of Aminophenazone can be decreased when it is combined with Efavirenz.Approved, Withdrawn
AminophyllineThe serum concentration of Aminophylline can be decreased when it is combined with Efavirenz.Approved
AmiodaroneThe metabolism of Efavirenz can be decreased when combined with Amiodarone.Approved, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Amisulpride is combined with Efavirenz.Approved, Investigational
AmitriptylineThe serum concentration of Amitriptyline can be decreased when it is combined with Efavirenz.Approved
AmlodipineThe serum concentration of Amlodipine can be decreased when it is combined with Efavirenz.Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Efavirenz.Approved, Illicit
AmodiaquineEfavirenz may increase the hepatotoxic activities of Amodiaquine.Approved
AmoxapineThe risk or severity of adverse effects can be increased when Amoxapine is combined with Efavirenz.Approved
AmoxicillinThe metabolism of Amoxicillin can be decreased when combined with Efavirenz.Approved, Vet Approved
AmperozideThe risk or severity of adverse effects can be increased when Amperozide is combined with Efavirenz.Experimental
AmprenavirThe serum concentration of Amprenavir can be decreased when it is combined with Efavirenz.Approved
AmrinoneThe serum concentration of Amrinone can be decreased when it is combined with Efavirenz.Approved
AntipyrineThe serum concentration of Antipyrine can be decreased when it is combined with Efavirenz.Approved
ApixabanThe serum concentration of Apixaban can be decreased when it is combined with Efavirenz.Approved
ApremilastThe serum concentration of Apremilast can be decreased when it is combined with Efavirenz.Approved, Investigational
AprepitantThe serum concentration of Efavirenz can be increased when it is combined with Aprepitant.Approved, Investigational
Arachidonic AcidThe metabolism of Arachidonic Acid can be decreased when combined with Efavirenz.Experimental
ArformoterolThe metabolism of Arformoterol can be decreased when combined with Efavirenz.Approved, Investigational
ArgatrobanThe serum concentration of Argatroban can be decreased when it is combined with Efavirenz.Approved, Investigational
AripiprazoleThe serum concentration of Aripiprazole can be decreased when it is combined with Efavirenz.Approved, Investigational
ArtemetherThe serum concentration of Artemether can be decreased when it is combined with Efavirenz.Approved
ArticaineThe risk or severity of adverse effects can be increased when Articaine is combined with Efavirenz.Approved
AsenapineThe serum concentration of Asenapine can be decreased when it is combined with Efavirenz.Approved
AstemizoleThe serum concentration of Astemizole can be decreased when it is combined with Efavirenz.Approved, Withdrawn
AtazanavirThe serum concentration of Atazanavir can be decreased when it is combined with Efavirenz.Approved, Investigational
AtomoxetineThe metabolism of Efavirenz can be decreased when combined with Atomoxetine.Approved
AtorvastatinThe serum concentration of Atorvastatin can be decreased when it is combined with Efavirenz.Approved
AtovaquoneThe serum concentration of Atovaquone can be decreased when it is combined with Efavirenz.Approved
AvanafilThe serum concentration of Avanafil can be decreased when it is combined with Efavirenz.Approved
AxitinibThe serum concentration of Axitinib can be decreased when it is combined with Efavirenz.Approved, Investigational
AzaperoneThe risk or severity of adverse effects can be increased when Azaperone is combined with Efavirenz.Vet Approved
AzelastineEfavirenz may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
AzelastineThe serum concentration of Azelastine can be decreased when it is combined with Efavirenz.Approved
AzelnidipineThe serum concentration of Azelnidipine can be decreased when it is combined with Efavirenz.Approved
AzimilideThe serum concentration of Azimilide can be decreased when it is combined with Efavirenz.Investigational
AzithromycinThe serum concentration of Azithromycin can be decreased when it is combined with Efavirenz.Approved
BaclofenThe risk or severity of adverse effects can be increased when Baclofen is combined with Efavirenz.Approved
BanoxantroneThe serum concentration of Banoxantrone can be decreased when it is combined with Efavirenz.Investigational
BarbitalThe risk or severity of adverse effects can be increased when Barbital is combined with Efavirenz.Illicit
BarnidipineThe serum concentration of Barnidipine can be decreased when it is combined with Efavirenz.Approved
BedaquilineThe serum concentration of Bedaquiline can be decreased when it is combined with Efavirenz.Approved
BenidipineThe serum concentration of Benidipine can be decreased when it is combined with Efavirenz.Approved
BenperidolThe risk or severity of adverse effects can be increased when Efavirenz is combined with Benperidol.Investigational
BenzatropineThe metabolism of Benzatropine can be decreased when combined with Efavirenz.Approved
BenzocaineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Efavirenz.Approved
BenzphetamineThe serum concentration of Benzphetamine can be decreased when it is combined with Efavirenz.Approved, Illicit
Benzyl alcoholThe serum concentration of Benzyl alcohol can be decreased when it is combined with Efavirenz.Approved
BepridilThe serum concentration of Bepridil can be decreased when it is combined with Efavirenz.Approved, Withdrawn
BeraprostThe metabolism of Beraprost can be decreased when combined with Efavirenz.Investigational
BexaroteneThe serum concentration of Efavirenz can be decreased when it is combined with Bexarotene.Approved, Investigational
BezafibrateThe serum concentration of Bezafibrate can be decreased when it is combined with Efavirenz.Approved
BicalutamideThe serum concentration of Bicalutamide can be decreased when it is combined with Efavirenz.Approved
BisoprololThe serum concentration of Bisoprolol can be decreased when it is combined with Efavirenz.Approved
BoceprevirThe serum concentration of Boceprevir can be decreased when it is combined with Efavirenz.Approved
BortezomibThe serum concentration of Bortezomib can be decreased when it is combined with Efavirenz.Approved, Investigational
BosentanThe serum concentration of Bosentan can be increased when it is combined with Efavirenz.Approved, Investigational
BosutinibThe serum concentration of Bosutinib can be decreased when it is combined with Efavirenz.Approved
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be decreased when it is combined with Efavirenz.Approved
BrexpiprazoleThe serum concentration of Brexpiprazole can be decreased when it is combined with Efavirenz.Approved
BrimonidineThe risk or severity of adverse effects can be increased when Brimonidine is combined with Efavirenz.Approved
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Efavirenz.Approved
BrinzolamideThe serum concentration of Brinzolamide can be decreased when it is combined with Efavirenz.Approved
BromazepamThe serum concentration of Bromazepam can be decreased when it is combined with Efavirenz.Approved, Illicit
BromocriptineThe serum concentration of Bromocriptine can be decreased when it is combined with Efavirenz.Approved, Investigational
BrompheniramineThe serum concentration of Brompheniramine can be decreased when it is combined with Efavirenz.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Brotizolam is combined with Efavirenz.Approved, Withdrawn
BudesonideThe serum concentration of Budesonide can be decreased when it is combined with Efavirenz.Approved
BupivacaineThe serum concentration of Bupivacaine can be decreased when it is combined with Efavirenz.Approved, Investigational
BuprenorphineThe serum concentration of the active metabolites of Buprenorphine can be reduced when Buprenorphine is used in combination with Efavirenz resulting in a loss in efficacy.Approved, Illicit, Investigational, Vet Approved
BupropionThe serum concentration of Bupropion can be decreased when it is combined with Efavirenz.Approved
BuspironeThe serum concentration of Buspirone can be decreased when it is combined with Efavirenz.Approved, Investigational
BusulfanThe serum concentration of Busulfan can be decreased when it is combined with Efavirenz.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Efavirenz.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Butacaine is combined with Efavirenz.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Butalbital is combined with Efavirenz.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Butamben is combined with Efavirenz.Approved
ButethalThe risk or severity of adverse effects can be increased when Butethal is combined with Efavirenz.Approved, Illicit
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Efavirenz.Approved, Illicit, Vet Approved
CabazitaxelThe serum concentration of Cabazitaxel can be decreased when it is combined with Efavirenz.Approved
CabergolineThe serum concentration of Cabergoline can be decreased when it is combined with Efavirenz.Approved
CabozantinibThe serum concentration of Cabozantinib can be decreased when it is combined with Efavirenz.Approved
CaffeineThe serum concentration of Caffeine can be decreased when it is combined with Efavirenz.Approved
CaiThe serum concentration of Cai can be decreased when it is combined with Efavirenz.Investigational
CalcitriolThe serum concentration of Calcitriol can be decreased when it is combined with Efavirenz.Approved, Nutraceutical
CanagliflozinThe serum concentration of Canagliflozin can be decreased when it is combined with Efavirenz.Approved
CandesartanThe metabolism of Candesartan can be decreased when combined with Efavirenz.Approved
CarbamazepineThe serum concentration of Efavirenz can be decreased when it is combined with Carbamazepine.Approved, Investigational
CarbinoxamineThe serum concentration of Carbinoxamine can be decreased when it is combined with Efavirenz.Approved
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Efavirenz.Illicit, Vet Approved
CariprazineThe serum concentration of Cariprazine can be decreased when it is combined with Efavirenz.Approved
CarisoprodolThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Efavirenz.Approved
CarvedilolThe serum concentration of Carvedilol can be increased when it is combined with Efavirenz.Approved, Investigational
CaspofunginThe serum concentration of Caspofungin can be decreased when it is combined with Efavirenz.Approved
CelecoxibThe serum concentration of Celecoxib can be decreased when it is combined with Efavirenz.Approved, Investigational
CeliprololThe serum concentration of Celiprolol can be decreased when it is combined with Efavirenz.Approved, Investigational
CephalexinThe serum concentration of Cephalexin can be decreased when it is combined with Efavirenz.Approved, Vet Approved
CeritinibThe serum concentration of Efavirenz can be increased when it is combined with Ceritinib.Approved
CerivastatinThe serum concentration of Cerivastatin can be decreased when it is combined with Efavirenz.Withdrawn
CetirizineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Efavirenz.Approved
CevimelineThe serum concentration of Cevimeline can be decreased when it is combined with Efavirenz.Approved
Chenodeoxycholic acidThe serum concentration of Chenodeoxycholic acid can be decreased when it is combined with Efavirenz.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Chloral hydrate is combined with Efavirenz.Approved, Illicit, Vet Approved
ChloramphenicolThe metabolism of Chloramphenicol can be decreased when combined with Efavirenz.Approved, Vet Approved
ChlordiazepoxideThe serum concentration of Chlordiazepoxide can be decreased when it is combined with Efavirenz.Approved, Illicit
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlormezanone is combined with Efavirenz.Approved, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Efavirenz.Approved
ChloroquineThe serum concentration of Chloroquine can be decreased when it is combined with Efavirenz.Approved, Vet Approved
ChlorphenamineThe serum concentration of Chlorphenamine can be decreased when it is combined with Efavirenz.Approved
ChlorpromazineThe serum concentration of Chlorpromazine can be decreased when it is combined with Efavirenz.Approved, Vet Approved
ChlorpropamideThe metabolism of Chlorpropamide can be decreased when combined with Efavirenz.Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Efavirenz.Approved, Withdrawn
ChlorzoxazoneThe serum concentration of Chlorzoxazone can be decreased when it is combined with Efavirenz.Approved
CholecalciferolThe serum concentration of Cholecalciferol can be decreased when it is combined with Efavirenz.Approved, Nutraceutical
CiclesonideThe serum concentration of Ciclesonide can be decreased when it is combined with Efavirenz.Approved, Investigational
CilnidipineThe serum concentration of Cilnidipine can be decreased when it is combined with Efavirenz.Approved
CilostazolThe serum concentration of Cilostazol can be increased when it is combined with Efavirenz.Approved
CinacalcetThe serum concentration of Cinacalcet can be decreased when it is combined with Efavirenz.Approved
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Efavirenz.Approved, Vet Approved
CinnarizineThe serum concentration of Cinnarizine can be decreased when it is combined with Efavirenz.Approved
CisaprideThe serum concentration of Cisapride can be decreased when it is combined with Efavirenz.Approved, Investigational, Withdrawn
CitalopramThe serum concentration of Citalopram can be increased when it is combined with Efavirenz.Approved
ClarithromycinThe serum concentration of Clarithromycin can be decreased when it is combined with Efavirenz.Approved
ClemastineThe metabolism of Efavirenz can be decreased when combined with Clemastine.Approved
ClevidipineThe serum concentration of Clevidipine can be decreased when it is combined with Efavirenz.Approved
ClidiniumThe risk or severity of adverse effects can be increased when Efavirenz is combined with Clidinium.Approved
ClindamycinThe serum concentration of Clindamycin can be decreased when it is combined with Efavirenz.Approved, Vet Approved
ClobazamThe serum concentration of Clobazam can be decreased when it is combined with Efavirenz.Approved, Illicit
ClofazimineThe serum concentration of Clofazimine can be decreased when it is combined with Efavirenz.Approved, Investigational
ClofibrateThe serum concentration of Clofibrate can be decreased when it is combined with Efavirenz.Approved
clomethiazoleThe serum concentration of clomethiazole can be decreased when it is combined with Efavirenz.Investigational
ClomipramineThe serum concentration of Clomipramine can be decreased when it is combined with Efavirenz.Approved, Vet Approved
ClonazepamThe serum concentration of Clonazepam can be decreased when it is combined with Efavirenz.Approved, Illicit
ClonidineThe serum concentration of Clonidine can be decreased when it is combined with Efavirenz.Approved
ClopidogrelThe serum concentration of the active metabolites of Clopidogrel can be reduced when Clopidogrel is used in combination with Efavirenz resulting in a loss in efficacy.Approved, Nutraceutical
ClorazepateThe serum concentration of Clorazepate can be decreased when it is combined with Efavirenz.Approved, Illicit
ClotiazepamThe serum concentration of Clotiazepam can be decreased when it is combined with Efavirenz.Approved, Illicit
ClotrimazoleThe metabolism of Efavirenz can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineThe serum concentration of Clozapine can be decreased when it is combined with Efavirenz.Approved
CobicistatThe metabolism of Efavirenz can be decreased when combined with Cobicistat.Approved
CobimetinibThe serum concentration of Cobimetinib can be decreased when it is combined with Efavirenz.Approved
CocaineThe serum concentration of Cocaine can be decreased when it is combined with Efavirenz.Approved, Illicit
CodeineThe serum concentration of Codeine can be decreased when it is combined with Efavirenz.Approved, Illicit
ColchicineThe serum concentration of Colchicine can be decreased when it is combined with Efavirenz.Approved
ConivaptanThe serum concentration of Efavirenz can be increased when it is combined with Conivaptan.Approved, Investigational
Conjugated Equine EstrogensThe serum concentration of Conjugated Equine Estrogens can be decreased when it is combined with Efavirenz.Approved
Cortisone acetateThe serum concentration of Cortisone acetate can be decreased when it is combined with Efavirenz.Approved
CrizotinibThe serum concentration of Crizotinib can be decreased when it is combined with Efavirenz.Approved
CyclizineThe risk or severity of adverse effects can be increased when Efavirenz is combined with Cyclizine.Approved
CyclobenzaprineThe serum concentration of Cyclobenzaprine can be decreased when it is combined with Efavirenz.Approved
CyclophosphamideThe serum concentration of Cyclophosphamide can be decreased when it is combined with Efavirenz.Approved, Investigational
CyclosporineThe serum concentration of Cyclosporine can be decreased when it is combined with Efavirenz.Approved, Investigational, Vet Approved
CyproheptadineThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with Efavirenz.Approved
CytarabineThe serum concentration of Cytarabine can be decreased when it is combined with Efavirenz.Approved, Investigational
DabrafenibThe serum concentration of Efavirenz can be decreased when it is combined with Dabrafenib.Approved
DaclatasvirThe serum concentration of Daclatasvir can be decreased when it is combined with Efavirenz.Approved
DantroleneThe serum concentration of Dantrolene can be decreased when it is combined with Efavirenz.Approved
DapagliflozinThe serum concentration of Dapagliflozin can be decreased when it is combined with Efavirenz.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Efavirenz.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Efavirenz is combined with Dapoxetine.Investigational
DapsoneThe serum concentration of Dapsone can be decreased when it is combined with Efavirenz.Approved, Investigational
DarifenacinThe serum concentration of Darifenacin can be decreased when it is combined with Efavirenz.Approved, Investigational
DarodipineThe serum concentration of Darodipine can be decreased when it is combined with Efavirenz.Experimental
DarunavirThe serum concentration of Efavirenz can be increased when it is combined with Darunavir.Approved
DasabuvirThe serum concentration of Dasabuvir can be decreased when it is combined with Efavirenz.Approved
DasatinibThe serum concentration of Efavirenz can be increased when it is combined with Dasatinib.Approved, Investigational
DaunorubicinThe serum concentration of Daunorubicin can be decreased when it is combined with Efavirenz.Approved
DeferasiroxThe serum concentration of Efavirenz can be decreased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe serum concentration of Efavirenz can be increased when it is combined with Delavirdine.Approved
deramciclaneThe risk or severity of adverse effects can be increased when deramciclane is combined with Efavirenz.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Efavirenz.Approved
DesipramineThe risk or severity of adverse effects can be increased when Efavirenz is combined with Desipramine.Approved
DesloratadineThe risk or severity of adverse effects can be increased when Efavirenz is combined with Desloratadine.Approved, Investigational
DesogestrelThe serum concentration of Desogestrel can be decreased when it is combined with Efavirenz.Approved
DesvenlafaxineThe serum concentration of Desvenlafaxine can be decreased when it is combined with Efavirenz.Approved
DetomidineThe risk or severity of adverse effects can be increased when Detomidine is combined with Efavirenz.Vet Approved
DexamethasoneThe serum concentration of Dexamethasone can be decreased when it is combined with Efavirenz.Approved, Investigational, Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Efavirenz.Approved
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Efavirenz.Approved, Vet Approved
DextromethorphanThe serum concentration of Dextromethorphan can be decreased when it is combined with Efavirenz.Approved
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Efavirenz.Experimental, Illicit
DextropropoxypheneThe serum concentration of Dextropropoxyphene can be decreased when it is combined with Efavirenz.Approved, Illicit, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Efavirenz.Approved
DiazepamThe serum concentration of Diazepam can be decreased when it is combined with Efavirenz.Approved, Illicit, Vet Approved
DiclofenacThe serum concentration of Diclofenac can be decreased when it is combined with Efavirenz.Approved, Vet Approved
DicoumarolThe serum concentration of Dicoumarol can be decreased when it is combined with Efavirenz.Approved
DienogestThe serum concentration of Dienogest can be decreased when it is combined with Efavirenz.Approved
DifenoxinThe risk or severity of adverse effects can be increased when Efavirenz is combined with Difenoxin.Approved, Illicit
DigitoxinThe serum concentration of Digitoxin can be decreased when it is combined with Efavirenz.Approved
DigoxinThe serum concentration of Digoxin can be decreased when it is combined with Efavirenz.Approved
DihydrocodeineThe serum concentration of Dihydrocodeine can be decreased when it is combined with Efavirenz.Approved, Illicit
DihydroergotamineThe serum concentration of Dihydroergotamine can be decreased when it is combined with Efavirenz.Approved
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Efavirenz.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Efavirenz.Experimental, Illicit
DiltiazemThe serum concentration of Diltiazem can be decreased when it is combined with Efavirenz.Approved
DimenhydrinateThe risk or severity of adverse effects can be increased when Efavirenz is combined with Dimenhydrinate.Approved
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Efavirenz.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Efavirenz.Approved, Illicit
DisopyramideThe serum concentration of Disopyramide can be decreased when it is combined with Efavirenz.Approved
DisulfiramThe serum concentration of Disulfiram can be decreased when it is combined with Efavirenz.Approved
DocetaxelThe serum concentration of Docetaxel can be decreased when it is combined with Efavirenz.Approved, Investigational
DofetilideThe serum concentration of Dofetilide can be decreased when it is combined with Efavirenz.Approved
DolasetronThe serum concentration of Dolasetron can be decreased when it is combined with Efavirenz.Approved
DolutegravirThe serum concentration of Dolutegravir can be decreased when it is combined with Efavirenz.Approved
DomperidoneThe serum concentration of Domperidone can be decreased when it is combined with Efavirenz.Approved, Investigational, Vet Approved
DonepezilThe serum concentration of Donepezil can be decreased when it is combined with Efavirenz.Approved
DopamineThe metabolism of Dopamine can be decreased when combined with Efavirenz.Approved
DoramectinThe risk or severity of adverse effects can be increased when Doramectin is combined with Efavirenz.Vet Approved
DorzolamideThe serum concentration of Dorzolamide can be decreased when it is combined with Efavirenz.Approved
DotarizineThe serum concentration of Dotarizine can be decreased when it is combined with Efavirenz.Investigational
DoxazosinThe metabolism of Doxazosin can be decreased when combined with Efavirenz.Approved
DoxepinThe serum concentration of Doxepin can be decreased when it is combined with Efavirenz.Approved
DoxorubicinThe serum concentration of Doxorubicin can be decreased when it is combined with Efavirenz.Approved, Investigational
DoxycyclineThe metabolism of Efavirenz can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Efavirenz.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when DPDPE is combined with Efavirenz.Investigational
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Efavirenz.Approved, Illicit
DronedaroneThe serum concentration of Dronedarone can be decreased when it is combined with Efavirenz.Approved
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Efavirenz.Approved, Vet Approved
DrospirenoneThe serum concentration of Drospirenone can be decreased when it is combined with Efavirenz.Approved
DrotebanolThe risk or severity of adverse effects can be increased when Drotebanol is combined with Efavirenz.Experimental, Illicit
DuloxetineThe risk or severity of adverse effects can be increased when Efavirenz is combined with Duloxetine.Approved
DutasterideThe serum concentration of Dutasteride can be decreased when it is combined with Efavirenz.Approved, Investigational
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Efavirenz.Approved
EcgonineThe risk or severity of adverse effects can be increased when Ecgonine is combined with Efavirenz.Experimental, Illicit
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when ECGONINE METHYL ESTER is combined with Efavirenz.Experimental
EcopipamThe risk or severity of adverse effects can be increased when Efavirenz is combined with Ecopipam.Investigational
EfonidipineThe serum concentration of Efonidipine can be decreased when it is combined with Efavirenz.Approved
EletriptanThe serum concentration of Eletriptan can be decreased when it is combined with Efavirenz.Approved, Investigational
EliglustatThe serum concentration of Eliglustat can be decreased when it is combined with Efavirenz.Approved
EltrombopagThe metabolism of Eltrombopag can be decreased when combined with Efavirenz.Approved
ElvitegravirThe serum concentration of Elvitegravir can be decreased when it is combined with Efavirenz.Approved
EnalaprilThe serum concentration of Enalapril can be decreased when it is combined with Efavirenz.Approved, Vet Approved
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Efavirenz.Approved, Vet Approved
EnfuvirtideThe metabolism of Enfuvirtide can be decreased when combined with Efavirenz.Approved, Investigational
EntacaponeThe risk or severity of adverse effects can be increased when Entacapone is combined with Efavirenz.Approved, Investigational
EnzalutamideThe serum concentration of Enzalutamide can be decreased when it is combined with Efavirenz.Approved
EperisoneThe serum concentration of Eperisone can be decreased when it is combined with Efavirenz.Approved, Investigational
EpinastineThe serum concentration of Epinastine can be decreased when it is combined with Efavirenz.Approved, Investigational
EplerenoneThe serum concentration of Eplerenone can be decreased when it is combined with Efavirenz.Approved
EpoprostenolThe metabolism of Epoprostenol can be decreased when combined with Efavirenz.Approved
ErgocalciferolThe serum concentration of Ergocalciferol can be decreased when it is combined with Efavirenz.Approved, Nutraceutical
Ergoloid mesylateThe serum concentration of Ergoloid mesylate can be decreased when it is combined with Efavirenz.Approved
ErgonovineThe serum concentration of Ergonovine can be decreased when it is combined with Efavirenz.Approved
ErgotamineThe serum concentration of Ergotamine can be decreased when it is combined with Efavirenz.Approved
ErlotinibThe serum concentration of Erlotinib can be decreased when it is combined with Efavirenz.Approved, Investigational
ErythromycinThe serum concentration of Erythromycin can be decreased when it is combined with Efavirenz.Approved, Vet Approved
EscitalopramThe serum concentration of Escitalopram can be decreased when it is combined with Efavirenz.Approved, Investigational
Eslicarbazepine acetateThe serum concentration of Efavirenz can be decreased when it is combined with Eslicarbazepine acetate.Approved
EsomeprazoleThe serum concentration of Esomeprazole can be decreased when it is combined with Efavirenz.Approved, Investigational
EstazolamThe serum concentration of Estazolam can be decreased when it is combined with Efavirenz.Approved, Illicit
EstradiolThe serum concentration of Estradiol can be decreased when it is combined with Efavirenz.Approved, Investigational, Vet Approved
Estradiol valerate/DienogestThe serum concentration of Estradiol valerate/Dienogest can be decreased when it is combined with Efavirenz.Approved
EstramustineThe serum concentration of Estramustine can be decreased when it is combined with Efavirenz.Approved
EstroneThe serum concentration of Estrone can be decreased when it is combined with Efavirenz.Approved
Estrone sulfateThe serum concentration of Estrone sulfate can be decreased when it is combined with Efavirenz.Approved
EszopicloneThe serum concentration of Eszopiclone can be decreased when it is combined with Efavirenz.Approved
EthanolThe risk or severity of adverse effects can be increased when Efavirenz is combined with Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Efavirenz.Approved, Illicit, Withdrawn
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be decreased when it is combined with Efavirenz.Approved
EthosuximideThe serum concentration of Ethosuximide can be decreased when it is combined with Efavirenz.Approved
EthotoinThe risk or severity of adverse effects can be increased when Efavirenz is combined with Ethotoin.Approved
Ethyl biscoumacetateThe serum concentration of Ethyl biscoumacetate can be decreased when it is combined with Efavirenz.Withdrawn
Ethyl carbamateThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Efavirenz.Withdrawn
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Efavirenz.Approved, Illicit
EthylmorphineThe serum concentration of Ethylmorphine can be decreased when it is combined with Efavirenz.Approved, Illicit
Ethynodiol diacetateThe serum concentration of Ethynodiol diacetate can be decreased when it is combined with Efavirenz.Approved
EtidocaineThe risk or severity of adverse effects can be increased when Etidocaine is combined with Efavirenz.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Etifoxine is combined with Efavirenz.Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Etizolam is combined with Efavirenz.Approved
EtodolacThe metabolism of Etodolac can be decreased when combined with Efavirenz.Approved, Investigational, Vet Approved
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Efavirenz.Approved
EtonogestrelThe therapeutic efficacy of Etonogestrel can be decreased when used in combination with Efavirenz.Approved, Investigational
EtoperidoneThe risk or severity of adverse effects can be increased when Efavirenz is combined with Etoperidone.Approved
EtoposideThe serum concentration of Etoposide can be decreased when it is combined with Efavirenz.Approved
EtoricoxibThe serum concentration of Etoricoxib can be decreased when it is combined with Efavirenz.Approved, Investigational
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Efavirenz.Illicit, Vet Approved
EtravirineThe serum concentration of Etravirine can be decreased when it is combined with Efavirenz.Approved
EverolimusThe serum concentration of Everolimus can be decreased when it is combined with Efavirenz.Approved
ExemestaneThe serum concentration of Exemestane can be decreased when it is combined with Efavirenz.Approved, Investigational
EzogabineThe risk or severity of adverse effects can be increased when Efavirenz is combined with Ezogabine.Approved
FamciclovirThe serum concentration of Famciclovir can be decreased when it is combined with Efavirenz.Approved
FamotidineThe metabolism of Famotidine can be decreased when combined with Efavirenz.Approved
FelbamateThe serum concentration of Felbamate can be decreased when it is combined with Efavirenz.Approved
FelodipineThe serum concentration of Felodipine can be decreased when it is combined with Efavirenz.Approved, Investigational
FencamfamineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Efavirenz.Approved, Illicit, Withdrawn
FendilineThe serum concentration of Fendiline can be decreased when it is combined with Efavirenz.Withdrawn
FenofibrateThe serum concentration of Fenofibrate can be decreased when it is combined with Efavirenz.Approved
FentanylThe serum concentration of Fentanyl can be decreased when it is combined with Efavirenz.Approved, Illicit, Investigational, Vet Approved
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Efavirenz.Approved
FexofenadineThe risk or severity of adverse effects can be increased when Efavirenz is combined with Fexofenadine.Approved
FinasterideThe serum concentration of Finasteride can be decreased when it is combined with Efavirenz.Approved
FingolimodThe serum concentration of Fingolimod can be decreased when it is combined with Efavirenz.Approved, Investigational
FlibanserinThe serum concentration of Flibanserin can be decreased when it is combined with Efavirenz.Approved
FluconazoleThe metabolism of Efavirenz can be decreased when combined with Fluconazole.Approved
FludiazepamThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Efavirenz.Approved, Illicit
FluindioneThe serum concentration of Fluindione can be decreased when it is combined with Efavirenz.Investigational
FlunarizineThe serum concentration of Flunarizine can be decreased when it is combined with Efavirenz.Approved
FlunisolideThe serum concentration of Flunisolide can be decreased when it is combined with Efavirenz.Approved, Investigational
FlunitrazepamThe serum concentration of Flunitrazepam can be decreased when it is combined with Efavirenz.Approved, Illicit
FluorometholoneThe serum concentration of Fluorometholone can be decreased when it is combined with Efavirenz.Approved
FluorouracilThe metabolism of Fluorouracil can be decreased when combined with Efavirenz.Approved
FluoxetineThe serum concentration of Fluoxetine can be decreased when it is combined with Efavirenz.Approved, Vet Approved
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Efavirenz.Approved, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Efavirenz.Approved
FlurazepamThe serum concentration of Flurazepam can be decreased when it is combined with Efavirenz.Approved, Illicit
FlurbiprofenThe metabolism of Flurbiprofen can be decreased when combined with Efavirenz.Approved, Investigational
FluspirileneThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Efavirenz.Approved
FlutamideThe serum concentration of Flutamide can be decreased when it is combined with Efavirenz.Approved
Fluticasone furoateThe serum concentration of Fluticasone furoate can be decreased when it is combined with Efavirenz.Approved
Fluticasone PropionateThe serum concentration of Fluticasone Propionate can be decreased when it is combined with Efavirenz.Approved
FluvastatinThe serum concentration of Fluvastatin can be decreased when it is combined with Efavirenz.Approved
FluvoxamineThe metabolism of Efavirenz can be decreased when combined with Fluvoxamine.Approved, Investigational
FormoterolThe metabolism of Formoterol can be decreased when combined with Efavirenz.Approved, Investigational
FosamprenavirThe serum concentration of the active metabolites of Fosamprenavir can be reduced when Fosamprenavir is used in combination with Efavirenz resulting in a loss in efficacy.Approved
FosaprepitantThe serum concentration of Efavirenz can be increased when it is combined with Fosaprepitant.Approved
FosphenytoinThe serum concentration of Efavirenz can be decreased when it is combined with Fosphenytoin.Approved
FospropofolThe risk or severity of adverse effects can be increased when Fospropofol is combined with Efavirenz.Approved, Illicit
FulvestrantThe serum concentration of Fulvestrant can be decreased when it is combined with Efavirenz.Approved, Investigational
Fusidic AcidThe serum concentration of Efavirenz can be increased when it is combined with Fusidic Acid.Approved
GabapentinThe serum concentration of Gabapentin can be decreased when it is combined with Efavirenz.Approved, Investigational
gabapentin enacarbilThe risk or severity of adverse effects can be increased when Efavirenz is combined with gabapentin enacarbil.Approved
GalantamineThe serum concentration of Galantamine can be decreased when it is combined with Efavirenz.Approved
GallopamilThe serum concentration of Gallopamil can be decreased when it is combined with Efavirenz.Investigational
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Efavirenz.Approved, Illicit
GavestinelThe metabolism of Gavestinel can be decreased when combined with Efavirenz.Investigational
GefitinibThe serum concentration of Gefitinib can be decreased when it is combined with Efavirenz.Approved, Investigational
GemfibrozilThe serum concentration of Gemfibrozil can be decreased when it is combined with Efavirenz.Approved
GepironeThe risk or severity of adverse effects can be increased when Efavirenz is combined with Gepirone.Investigational
GestodeneThe serum concentration of Gestodene can be decreased when it is combined with Efavirenz.Approved
Ginkgo bilobaThe serum concentration of Efavirenz can be decreased when it is combined with Ginkgo biloba.Approved, Nutraceutical
GliclazideThe metabolism of Gliclazide can be decreased when combined with Efavirenz.Approved
GlimepirideThe metabolism of Glimepiride can be decreased when combined with Efavirenz.Approved
GlipizideThe serum concentration of Glipizide can be decreased when it is combined with Efavirenz.Approved
GlucosamineThe metabolism of Glucosamine can be decreased when combined with Efavirenz.Approved
GlutethimideThe risk or severity of adverse effects can be increased when Glutethimide is combined with Efavirenz.Approved, Illicit
GlyburideThe serum concentration of Glyburide can be decreased when it is combined with Efavirenz.Approved
GranisetronThe serum concentration of Granisetron can be decreased when it is combined with Efavirenz.Approved, Investigational
GrepafloxacinThe serum concentration of Grepafloxacin can be decreased when it is combined with Efavirenz.Withdrawn
GuanfacineThe serum concentration of Guanfacine can be decreased when it is combined with Efavirenz.Approved, Investigational
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Efavirenz.Approved, Illicit, Withdrawn
HalofantrineThe serum concentration of Halofantrine can be decreased when it is combined with Efavirenz.Approved
HaloperidolThe serum concentration of Haloperidol can be decreased when it is combined with Efavirenz.Approved
HalothaneThe serum concentration of Halothane can be decreased when it is combined with Efavirenz.Approved, Vet Approved
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Efavirenz.Approved, Illicit
HexobarbitalThe serum concentration of Hexobarbital can be decreased when it is combined with Efavirenz.Approved
Histamine PhosphateThe serum concentration of Histamine Phosphate can be decreased when it is combined with Efavirenz.Approved
HydrocodoneEfavirenz may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydrocortisoneThe serum concentration of Hydrocortisone can be decreased when it is combined with Efavirenz.Approved, Vet Approved
HydromorphoneThe serum concentration of Hydromorphone can be decreased when it is combined with Efavirenz.Approved, Illicit
Hydroxyprogesterone caproateThe serum concentration of Hydroxyprogesterone caproate can be decreased when it is combined with Efavirenz.Approved
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Efavirenz.Approved
IbrutinibThe serum concentration of Ibrutinib can be decreased when it is combined with Efavirenz.Approved
IbuprofenThe metabolism of Ibuprofen can be decreased when combined with Efavirenz.Approved
IdarubicinThe metabolism of Idarubicin can be decreased when combined with Efavirenz.Approved
IdelalisibThe serum concentration of Efavirenz can be increased when it is combined with Idelalisib.Approved
IfosfamideThe serum concentration of the active metabolites of Ifosfamide can be reduced when Ifosfamide is used in combination with Efavirenz resulting in a loss in efficacy.Approved
IloperidoneThe serum concentration of Iloperidone can be decreased when it is combined with Efavirenz.Approved
ImatinibThe serum concentration of Imatinib can be decreased when it is combined with Efavirenz.Approved
ImipramineThe serum concentration of Imipramine can be decreased when it is combined with Efavirenz.Approved
ImiquimodThe serum concentration of Imiquimod can be decreased when it is combined with Efavirenz.Approved, Investigational
IndacaterolThe serum concentration of Indacaterol can be decreased when it is combined with Efavirenz.Approved
IndalpineThe risk or severity of adverse effects can be increased when Efavirenz is combined with Indalpine.Investigational, Withdrawn
IndapamideThe serum concentration of Indapamide can be decreased when it is combined with Efavirenz.Approved
IndinavirThe serum concentration of Indinavir can be decreased when it is combined with Efavirenz.Approved
indisulamThe metabolism of indisulam can be decreased when combined with Efavirenz.Investigational
IndomethacinThe metabolism of Indomethacin can be decreased when combined with Efavirenz.Approved, Investigational
Ipratropium bromideThe serum concentration of Ipratropium bromide can be decreased when it is combined with Efavirenz.Approved
IrbesartanThe metabolism of Irbesartan can be decreased when combined with Efavirenz.Approved, Investigational
IrinotecanThe serum concentration of Irinotecan can be decreased when it is combined with Efavirenz.Approved, Investigational
IsavuconazoniumThe serum concentration of Isavuconazonium can be decreased when it is combined with Efavirenz.Approved, Investigational
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Efavirenz.Approved, Vet Approved
Isosorbide DinitrateThe serum concentration of Isosorbide Dinitrate can be decreased when it is combined with Efavirenz.Approved
Isosorbide MononitrateThe serum concentration of Isosorbide Mononitrate can be decreased when it is combined with Efavirenz.Approved
IsradipineThe serum concentration of Isradipine can be decreased when it is combined with Efavirenz.Approved
ItraconazoleThe serum concentration of Itraconazole can be decreased when it is combined with Efavirenz.Approved, Investigational
IvabradineThe serum concentration of Ivabradine can be decreased when it is combined with Efavirenz.Approved
IvacaftorThe serum concentration of Efavirenz can be increased when it is combined with Ivacaftor.Approved
IvermectinThe serum concentration of Ivermectin can be decreased when it is combined with Efavirenz.Approved, Vet Approved
IxabepiloneThe serum concentration of Ixabepilone can be decreased when it is combined with Efavirenz.Approved, Investigational
IxazomibThe serum concentration of Ixazomib can be decreased when it is combined with Efavirenz.Approved
KetamineThe serum concentration of Ketamine can be decreased when it is combined with Efavirenz.Approved, Vet Approved
KetazolamThe serum concentration of Ketazolam can be decreased when it is combined with Efavirenz.Approved
KetobemidoneThe serum concentration of Ketobemidone can be decreased when it is combined with Efavirenz.Approved
KetoconazoleThe serum concentration of Ketoconazole can be decreased when it is combined with Efavirenz.Approved, Investigational
KetoconazoleThe metabolism of Efavirenz can be decreased when combined with Ketoconazole.Approved, Investigational
KetoprofenThe metabolism of Ketoprofen can be decreased when combined with Efavirenz.Approved, Vet Approved
LacidipineThe serum concentration of Lacidipine can be decreased when it is combined with Efavirenz.Approved
LamotrigineThe serum concentration of Lamotrigine can be decreased when it is combined with Efavirenz.Approved, Investigational
LansoprazoleThe serum concentration of Lansoprazole can be decreased when it is combined with Efavirenz.Approved, Investigational
LapatinibThe serum concentration of Lapatinib can be decreased when it is combined with Efavirenz.Approved, Investigational
LaquinimodThe serum concentration of Laquinimod can be decreased when it is combined with Efavirenz.Investigational
LeflunomideThe metabolism of Leflunomide can be decreased when combined with Efavirenz.Approved, Investigational
LenvatinibThe serum concentration of Lenvatinib can be decreased when it is combined with Efavirenz.Approved
LercanidipineThe serum concentration of Lercanidipine can be decreased when it is combined with Efavirenz.Approved, Investigational
LesinuradThe metabolism of Lesinurad can be decreased when combined with Efavirenz.Approved
LetrozoleThe serum concentration of Letrozole can be decreased when it is combined with Efavirenz.Approved, Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when Efavirenz is combined with Levetiracetam.Approved, Investigational
LevobupivacaineThe serum concentration of Levobupivacaine can be decreased when it is combined with Efavirenz.Approved
LevocabastineThe risk or severity of adverse effects can be increased when Efavirenz is combined with Levocabastine.Approved
LevocetirizineThe serum concentration of Levocetirizine can be decreased when it is combined with Efavirenz.Approved
LevodopaThe risk or severity of adverse effects can be increased when Efavirenz is combined with Levodopa.Approved
Levomethadyl AcetateThe serum concentration of Levomethadyl Acetate can be decreased when it is combined with Efavirenz.Approved
LevomilnacipranThe serum concentration of Levomilnacipran can be decreased when it is combined with Efavirenz.Approved
LevonorgestrelThe serum concentration of Levonorgestrel can be decreased when it is combined with Efavirenz.Approved, Investigational
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Efavirenz.Approved
LevothyroxineThe serum concentration of Levothyroxine can be decreased when it is combined with Efavirenz.Approved
LicofeloneThe metabolism of Licofelone can be decreased when combined with Efavirenz.Investigational
LidocaineThe serum concentration of Lidocaine can be decreased when it is combined with Efavirenz.Approved, Vet Approved
LisurideThe serum concentration of Lisuride can be decreased when it is combined with Efavirenz.Approved
LithiumThe risk or severity of adverse effects can be increased when Lithium is combined with Efavirenz.Approved
LofentanilThe risk or severity of adverse effects can be increased when Lofentanil is combined with Efavirenz.Illicit
LomitapideThe serum concentration of Lomitapide can be decreased when it is combined with Efavirenz.Approved
LoperamideThe serum concentration of Loperamide can be decreased when it is combined with Efavirenz.Approved
LopinavirThe serum concentration of Lopinavir can be decreased when it is combined with Efavirenz.Approved
LoratadineThe serum concentration of Loratadine can be decreased when it is combined with Efavirenz.Approved
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Efavirenz.Approved
LorcaserinThe serum concentration of Lorcaserin can be decreased when it is combined with Efavirenz.Approved
LornoxicamThe metabolism of Lornoxicam can be decreased when combined with Efavirenz.Approved
LosartanThe serum concentration of Losartan can be decreased when it is combined with Efavirenz.Approved
LovastatinThe serum concentration of Lovastatin can be decreased when it is combined with Efavirenz.Approved, Investigational
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Efavirenz.Approved
Lu AA21004The risk or severity of adverse effects can be increased when Lu AA21004 is combined with Efavirenz.Investigational
LuliconazoleThe serum concentration of Efavirenz can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Efavirenz can be decreased when it is combined with Lumacaftor.Approved
LumefantrineThe serum concentration of Lumefantrine can be decreased when it is combined with Efavirenz.Approved
LumiracoxibThe metabolism of Lumiracoxib can be decreased when combined with Efavirenz.Approved, Investigational
LurasidoneThe serum concentration of Lurasidone can be decreased when it is combined with Efavirenz.Approved
LynestrenolThe serum concentration of Lynestrenol can be decreased when it is combined with Efavirenz.Investigational
MacitentanThe serum concentration of Macitentan can be decreased when it is combined with Efavirenz.Approved
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Efavirenz.Approved, Vet Approved
ManidipineThe serum concentration of Manidipine can be decreased when it is combined with Efavirenz.Approved
MaprotilineThe risk or severity of adverse effects can be increased when Efavirenz is combined with Maprotiline.Approved
MaravirocThe serum concentration of Maraviroc can be decreased when it is combined with Efavirenz.Approved, Investigational
MebendazoleThe serum concentration of Mebendazole can be decreased when it is combined with Efavirenz.Approved, Vet Approved
MeclizineThe risk or severity of adverse effects can be increased when Efavirenz is combined with Meclizine.Approved
MedetomidineThe risk or severity of adverse effects can be increased when Medetomidine is combined with Efavirenz.Vet Approved
Medroxyprogesterone acetateThe serum concentration of Medroxyprogesterone acetate can be decreased when it is combined with Efavirenz.Approved, Investigational
Mefenamic acidThe metabolism of Mefenamic acid can be decreased when combined with Efavirenz.Approved
MefloquineThe serum concentration of Mefloquine can be decreased when it is combined with Efavirenz.Approved
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with Efavirenz.Approved, Nutraceutical, Vet Approved
MeloxicamThe serum concentration of Meloxicam can be decreased when it is combined with Efavirenz.Approved, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Melperone is combined with Efavirenz.Approved
MephenytoinThe metabolism of Mephenytoin can be decreased when combined with Efavirenz.Investigational, Withdrawn
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Efavirenz.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Efavirenz.Approved, Illicit
MesoridazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Efavirenz.Approved
MestranolThe metabolism of Mestranol can be decreased when combined with Efavirenz.Approved
MetaxaloneThe risk or severity of adverse effects can be increased when Efavirenz is combined with Metaxalone.Approved
MethadoneThe metabolism of Methadone can be increased when combined with Efavirenz.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Efavirenz.Approved, Illicit
MethapyrileneThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Efavirenz.Withdrawn
MethaqualoneThe serum concentration of Methaqualone can be decreased when it is combined with Efavirenz.Illicit, Withdrawn
MethocarbamolThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Efavirenz.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Efavirenz.Approved
MethotrimeprazineEfavirenz may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
MethoxsalenThe serum concentration of Methoxsalen can be decreased when it is combined with Efavirenz.Approved
MethoxyfluraneThe serum concentration of Methoxyflurane can be decreased when it is combined with Efavirenz.Approved, Vet Approved
MethsuximideThe risk or severity of adverse effects can be increased when Efavirenz is combined with Methsuximide.Approved
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Efavirenz.Approved
MethylprednisoloneThe serum concentration of Methylprednisolone can be decreased when it is combined with Efavirenz.Approved, Vet Approved
MethyltestosteroneThe serum concentration of Methyltestosterone can be decreased when it is combined with Efavirenz.Approved
MetoprololThe serum concentration of Metoprolol can be increased when it is combined with Efavirenz.Approved, Investigational
MetronidazoleThe serum concentration of Metronidazole can be decreased when it is combined with Efavirenz.Approved
MetyrosineEfavirenz may increase the sedative activities of Metyrosine.Approved
MexiletineThe serum concentration of Mexiletine can be decreased when it is combined with Efavirenz.Approved
MianserinThe serum concentration of Mianserin can be decreased when it is combined with Efavirenz.Approved
MibefradilThe serum concentration of Mibefradil can be decreased when it is combined with Efavirenz.Withdrawn
MiconazoleThe serum concentration of Miconazole can be decreased when it is combined with Efavirenz.Approved, Investigational, Vet Approved
MidazolamThe serum concentration of Midazolam can be decreased when it is combined with Efavirenz.Approved, Illicit
MifepristoneThe serum concentration of Efavirenz can be increased when it is combined with Mifepristone.Approved, Investigational
MilnacipranThe risk or severity of adverse effects can be increased when Efavirenz is combined with Milnacipran.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Efavirenz.Approved, Investigational
MirabegronThe serum concentration of Mirabegron can be decreased when it is combined with Efavirenz.Approved
MirtazapineEfavirenz may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MitotaneThe serum concentration of Efavirenz can be decreased when it is combined with Mitotane.Approved
MoclobemideThe metabolism of Moclobemide can be decreased when combined with Efavirenz.Approved
ModafinilThe serum concentration of Modafinil can be decreased when it is combined with Efavirenz.Approved, Investigational
MolindoneThe risk or severity of adverse effects can be increased when Molindone is combined with Efavirenz.Approved
MontelukastThe serum concentration of Montelukast can be decreased when it is combined with Efavirenz.Approved
MorphineThe serum concentration of Morphine can be decreased when it is combined with Efavirenz.Approved, Investigational
muraglitazarThe metabolism of muraglitazar can be decreased when combined with Efavirenz.Investigational
Mycophenolate mofetilThe serum concentration of Mycophenolate mofetil can be decreased when it is combined with Efavirenz.Approved, Investigational
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Efavirenz.Approved, Investigational
NafcillinThe serum concentration of Efavirenz can be decreased when it is combined with Nafcillin.Approved
NaftopidilThe serum concentration of Naftopidil can be decreased when it is combined with Efavirenz.Investigational
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Efavirenz.Approved
NaloxegolThe serum concentration of Naloxegol can be decreased when it is combined with Efavirenz.Approved
NaloxoneThe serum concentration of Naloxone can be decreased when it is combined with Efavirenz.Approved, Vet Approved
NaproxenThe metabolism of Naproxen can be decreased when combined with Efavirenz.Approved, Vet Approved
NateglinideThe serum concentration of Nateglinide can be decreased when it is combined with Efavirenz.Approved, Investigational
NefazodoneThe metabolism of Efavirenz can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe metabolism of Efavirenz can be decreased when combined with Nelfinavir.Approved
NetupitantThe serum concentration of Efavirenz can be increased when it is combined with Netupitant.Approved
NevirapineThe risk or severity of adverse effects can be increased when Efavirenz is combined with Nevirapine.Approved
NicardipineThe serum concentration of Nicardipine can be decreased when it is combined with Efavirenz.Approved
NiclosamideThe metabolism of Niclosamide can be decreased when combined with Efavirenz.Approved, Vet Approved
NicotineThe serum concentration of Nicotine can be decreased when it is combined with Efavirenz.Approved
NifedipineThe serum concentration of Nifedipine can be decreased when it is combined with Efavirenz.Approved
NiguldipineThe serum concentration of Niguldipine can be decreased when it is combined with Efavirenz.Experimental
NilotinibThe serum concentration of Nilotinib can be decreased when it is combined with Efavirenz.Approved, Investigational
NiludipineThe serum concentration of Niludipine can be decreased when it is combined with Efavirenz.Experimental
NilutamideThe metabolism of Nilutamide can be decreased when combined with Efavirenz.Approved
NilvadipineThe serum concentration of Nilvadipine can be decreased when it is combined with Efavirenz.Approved
NimesulideThe serum concentration of Nimesulide can be decreased when it is combined with Efavirenz.Approved, Withdrawn
NimodipineThe serum concentration of Nimodipine can be decreased when it is combined with Efavirenz.Approved
NisoldipineThe serum concentration of Nisoldipine can be decreased when it is combined with Efavirenz.Approved
NitrazepamThe serum concentration of Nitrazepam can be decreased when it is combined with Efavirenz.Approved
NitrendipineThe serum concentration of Nitrendipine can be decreased when it is combined with Efavirenz.Approved
Nitrous oxideThe risk or severity of adverse effects can be increased when Nitrous oxide is combined with Efavirenz.Approved, Vet Approved
NorelgestrominThe serum concentration of Norelgestromin can be decreased when it is combined with Efavirenz.Approved
NorethisteroneThe serum concentration of Norethisterone can be decreased when it is combined with Efavirenz.Approved
NorgestimateThe serum concentration of the active metabolites of Norgestimate can be reduced when Norgestimate is used in combination with Efavirenz resulting in a loss in efficacy.Approved
NorgestrelThe serum concentration of Norgestrel can be decreased when it is combined with Efavirenz.Approved
NormethadoneThe risk or severity of adverse effects can be increased when Normethadone is combined with Efavirenz.Approved, Illicit
NortriptylineThe serum concentration of Nortriptyline can be decreased when it is combined with Efavirenz.Approved
OlanzapineThe risk or severity of adverse effects can be increased when Olanzapine is combined with Efavirenz.Approved, Investigational
OlaparibThe serum concentration of Olaparib can be decreased when it is combined with Efavirenz.Approved
OlodaterolThe metabolism of Olodaterol can be decreased when combined with Efavirenz.Approved
OlopatadineThe serum concentration of Olopatadine can be decreased when it is combined with Efavirenz.Approved
OmbitasvirThe metabolism of Ombitasvir can be decreased when combined with Efavirenz.Approved
OmeprazoleThe serum concentration of Omeprazole can be decreased when it is combined with Efavirenz.Approved, Investigational, Vet Approved
OndansetronThe serum concentration of Ondansetron can be decreased when it is combined with Efavirenz.Approved
OpiumThe risk or severity of adverse effects can be increased when Opium is combined with Efavirenz.Approved, Illicit
OrphenadrineEfavirenz may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Osanetant is combined with Efavirenz.Investigational
OsimertinibThe serum concentration of Efavirenz can be increased when it is combined with Osimertinib.Approved
OspemifeneThe serum concentration of Ospemifene can be decreased when it is combined with Efavirenz.Approved
OxaprozinThe metabolism of Oxaprozin can be decreased when combined with Efavirenz.Approved
OxazepamThe serum concentration of Oxazepam can be decreased when it is combined with Efavirenz.Approved
OxetacaineThe risk or severity of adverse effects can be increased when Efavirenz is combined with Oxetacaine.Investigational
OxiconazoleThe metabolism of Oxiconazole can be decreased when combined with Efavirenz.Approved
OxprenololThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Efavirenz.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Efavirenz.Approved
OxybutyninThe serum concentration of Oxybutynin can be decreased when it is combined with Efavirenz.Approved, Investigational
OxycodoneThe serum concentration of Oxycodone can be decreased when it is combined with Efavirenz.Approved, Illicit, Investigational
OxymorphoneThe serum concentration of Oxymorphone can be decreased when it is combined with Efavirenz.Approved, Investigational, Vet Approved
PaclitaxelThe serum concentration of Paclitaxel can be decreased when it is combined with Efavirenz.Approved, Vet Approved
PalbociclibThe serum concentration of Palbociclib can be decreased when it is combined with Efavirenz.Approved
PaliperidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Efavirenz.Approved
PalonosetronThe serum concentration of Palonosetron can be decreased when it is combined with Efavirenz.Approved, Investigational
PanobinostatThe serum concentration of Panobinostat can be decreased when it is combined with Efavirenz.Approved, Investigational
PantoprazoleThe serum concentration of Pantoprazole can be decreased when it is combined with Efavirenz.Approved
ParaldehydeEfavirenz may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved
ParamethadioneThe serum concentration of Paramethadione can be decreased when it is combined with Efavirenz.Approved
ParamethasoneThe serum concentration of Paramethasone can be decreased when it is combined with Efavirenz.Approved
ParecoxibThe serum concentration of Parecoxib can be decreased when it is combined with Efavirenz.Approved
ParicalcitolThe serum concentration of Paricalcitol can be decreased when it is combined with Efavirenz.Approved, Investigational
ParitaprevirThe serum concentration of Paritaprevir can be decreased when it is combined with Efavirenz.Approved
ParoxetineThe metabolism of Efavirenz can be decreased when combined with Paroxetine.Approved, Investigational
PazopanibThe serum concentration of Pazopanib can be decreased when it is combined with Efavirenz.Approved
PentamidineThe serum concentration of Pentamidine can be decreased when it is combined with Efavirenz.Approved
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Efavirenz.Approved, Vet Approved
PentobarbitalThe metabolism of Efavirenz can be increased when combined with Pentobarbital.Approved, Vet Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Efavirenz.Approved
PerazineThe risk or severity of adverse effects can be increased when Efavirenz is combined with Perazine.Investigational
PergolideThe serum concentration of Pergolide can be decreased when it is combined with Efavirenz.Approved, Vet Approved, Withdrawn
PerhexilineThe serum concentration of Perhexiline can be decreased when it is combined with Efavirenz.Approved
PermethrinThe serum concentration of Permethrin can be decreased when it is combined with Efavirenz.Approved, Investigational
PerospironeThe risk or severity of adverse effects can be increased when Perospirone is combined with Efavirenz.Approved
PerphenazineThe serum concentration of Perphenazine can be decreased when it is combined with Efavirenz.Approved
PethidineThe serum concentration of Pethidine can be decreased when it is combined with Efavirenz.Approved
PhenacetinThe serum concentration of Phenacetin can be decreased when it is combined with Efavirenz.Withdrawn
PhenindioneThe serum concentration of Phenindione can be decreased when it is combined with Efavirenz.Approved
PhenobarbitalThe metabolism of Efavirenz can be increased when combined with Phenobarbital.Approved
PhenoxybenzamineThe serum concentration of Phenoxybenzamine can be decreased when it is combined with Efavirenz.Approved
PhenoxyethanolThe risk or severity of adverse effects can be increased when Phenoxyethanol is combined with Efavirenz.Approved
PhenprocoumonThe serum concentration of Phenprocoumon can be decreased when it is combined with Efavirenz.Approved
PhenylbutazoneThe metabolism of Phenylbutazone can be decreased when combined with Efavirenz.Approved, Vet Approved
PhenytoinThe serum concentration of Efavirenz can be decreased when it is combined with Phenytoin.Approved, Vet Approved
PilocarpineThe serum concentration of Pilocarpine can be decreased when it is combined with Efavirenz.Approved
PimecrolimusThe serum concentration of Pimecrolimus can be decreased when it is combined with Efavirenz.Approved, Investigational
PimozideThe serum concentration of Pimozide can be decreased when it is combined with Efavirenz.Approved
PinacidilThe serum concentration of Pinacidil can be decreased when it is combined with Efavirenz.Withdrawn
PinaveriumThe serum concentration of Pinaverium can be decreased when it is combined with Efavirenz.Approved
PioglitazoneThe serum concentration of Pioglitazone can be decreased when it is combined with Efavirenz.Approved, Investigational
PipamperoneThe risk or severity of adverse effects can be increased when Pipamperone is combined with Efavirenz.Approved
PipotiazineThe serum concentration of Pipotiazine can be decreased when it is combined with Efavirenz.Approved
PiritramideThe risk or severity of adverse effects can be increased when Efavirenz is combined with Piritramide.Investigational
PiroxicamThe metabolism of Piroxicam can be decreased when combined with Efavirenz.Approved, Investigational
PitavastatinThe metabolism of Pitavastatin can be decreased when combined with Efavirenz.Approved
PizotifenThe risk or severity of adverse effects can be increased when Efavirenz is combined with Pizotifen.Approved
PodofiloxThe serum concentration of Podofilox can be decreased when it is combined with Efavirenz.Approved
PomalidomideThe serum concentration of Pomalidomide can be decreased when it is combined with Efavirenz.Approved
PonatinibThe serum concentration of Ponatinib can be decreased when it is combined with Efavirenz.Approved
PosaconazoleThe serum concentration of Posaconazole can be decreased when it is combined with Efavirenz.Approved, Investigational, Vet Approved
PramipexoleEfavirenz may increase the sedative activities of Pramipexole.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Pramocaine is combined with Efavirenz.Approved
PrasteroneThe serum concentration of Prasterone can be decreased when it is combined with Efavirenz.Approved, Nutraceutical
PrasugrelThe serum concentration of Prasugrel can be decreased when it is combined with Efavirenz.Approved
PravastatinThe serum concentration of Pravastatin can be decreased when it is combined with Efavirenz.Approved
PrazepamThe serum concentration of Prazepam can be decreased when it is combined with Efavirenz.Approved, Illicit
PraziquantelThe serum concentration of Praziquantel can be decreased when it is combined with Efavirenz.Approved, Vet Approved
PrednisoloneThe serum concentration of Prednisolone can be decreased when it is combined with Efavirenz.Approved, Vet Approved
PrednisoneThe serum concentration of Prednisone can be decreased when it is combined with Efavirenz.Approved, Vet Approved
PregabalinThe serum concentration of Pregabalin can be decreased when it is combined with Efavirenz.Approved, Illicit, Investigational
PregnanoloneThe risk or severity of adverse effects can be increased when Efavirenz is combined with Pregnanolone.Investigational
PrenylamineThe serum concentration of Prenylamine can be decreased when it is combined with Efavirenz.Withdrawn
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Efavirenz.Approved
PrimaquineThe serum concentration of Primaquine can be decreased when it is combined with Efavirenz.Approved
PrimidoneThe metabolism of Efavirenz can be increased when combined with Primidone.Approved, Vet Approved
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Efavirenz.Approved, Investigational, Vet Approved
ProchlorperazineThe serum concentration of Prochlorperazine can be decreased when it is combined with Efavirenz.Approved, Vet Approved
ProgesteroneThe serum concentration of Progesterone can be decreased when it is combined with Efavirenz.Approved, Vet Approved
ProguanilThe serum concentration of Proguanil can be decreased when it is combined with Efavirenz.Approved
PromazineThe serum concentration of Promazine can be decreased when it is combined with Efavirenz.Approved, Vet Approved
PromethazineThe risk or severity of adverse effects can be increased when Efavirenz is combined with Promethazine.Approved
PropafenoneThe serum concentration of Propafenone can be decreased when it is combined with Efavirenz.Approved
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Efavirenz.Approved, Vet Approved
PropofolThe serum concentration of Propofol can be decreased when it is combined with Efavirenz.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Propoxycaine is combined with Efavirenz.Approved
PropranololThe serum concentration of Propranolol can be decreased when it is combined with Efavirenz.Approved, Investigational
ProtriptylineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Efavirenz.Approved
PSD502The risk or severity of adverse effects can be increased when PSD502 is combined with Efavirenz.Investigational
PyrazinamideThe serum concentration of Pyrazinamide can be decreased when it is combined with Efavirenz.Approved
QuazepamThe serum concentration of Efavirenz can be increased when it is combined with Quazepam.Approved, Illicit
QuetiapineThe serum concentration of Quetiapine can be decreased when it is combined with Efavirenz.Approved
QuinacrineThe serum concentration of Quinacrine can be decreased when it is combined with Efavirenz.Approved
QuinidineThe serum concentration of Quinidine can be decreased when it is combined with Efavirenz.Approved
QuinineThe serum concentration of Quinine can be decreased when it is combined with Efavirenz.Approved
RabeprazoleThe serum concentration of Rabeprazole can be decreased when it is combined with Efavirenz.Approved, Investigational
RacloprideThe risk or severity of adverse effects can be increased when Efavirenz is combined with Raclopride.Investigational
RaloxifeneThe serum concentration of Raloxifene can be decreased when it is combined with Efavirenz.Approved, Investigational
RamelteonThe serum concentration of Ramelteon can be decreased when it is combined with Efavirenz.Approved, Investigational
RanitidineThe metabolism of Ranitidine can be decreased when combined with Efavirenz.Approved
RanolazineThe serum concentration of Ranolazine can be decreased when it is combined with Efavirenz.Approved, Investigational
ReboxetineThe serum concentration of Reboxetine can be decreased when it is combined with Efavirenz.Approved, Investigational
RegorafenibThe serum concentration of Regorafenib can be decreased when it is combined with Efavirenz.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Efavirenz.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Efavirenz.Approved, Withdrawn
RepaglinideThe serum concentration of Repaglinide can be decreased when it is combined with Efavirenz.Approved, Investigational
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Efavirenz.Approved
RetapamulinThe serum concentration of Retapamulin can be decreased when it is combined with Efavirenz.Approved
RifabutinThe serum concentration of Rifabutin can be decreased when it is combined with Efavirenz.Approved
RifampicinThe serum concentration of Efavirenz can be decreased when it is combined with Rifampicin.Approved
RifapentineThe metabolism of Efavirenz can be increased when combined with Rifapentine.Approved
RilpivirineThe serum concentration of Rilpivirine can be increased when it is combined with Efavirenz.Approved
RimonabantThe serum concentration of Rimonabant can be decreased when it is combined with Efavirenz.Approved, Investigational
RiociguatThe serum concentration of Riociguat can be decreased when it is combined with Efavirenz.Approved
RisedronateThe serum concentration of Risedronate can be decreased when it is combined with Efavirenz.Approved, Investigational
RisperidoneThe serum concentration of Risperidone can be decreased when it is combined with Efavirenz.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Efavirenz is combined with Ritanserin.Investigational
RitonavirThe risk or severity of adverse effects can be increased when Efavirenz is combined with Ritonavir.Approved, Investigational
RivaroxabanThe serum concentration of Rivaroxaban can be decreased when it is combined with Efavirenz.Approved
RofecoxibThe serum concentration of Rofecoxib can be decreased when it is combined with Efavirenz.Investigational, Withdrawn
RolapitantThe serum concentration of Rolapitant can be decreased when it is combined with Efavirenz.Approved
RomidepsinThe serum concentration of Romidepsin can be decreased when it is combined with Efavirenz.Approved, Investigational
RomifidineThe risk or severity of adverse effects can be increased when Romifidine is combined with Efavirenz.Vet Approved
RopiniroleEfavirenz may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineThe serum concentration of Ropivacaine can be decreased when it is combined with Efavirenz.Approved
RosiglitazoneThe metabolism of Rosiglitazone can be decreased when combined with Efavirenz.Approved, Investigational
RosuvastatinThe serum concentration of Rosuvastatin can be decreased when it is combined with Efavirenz.Approved
RotigotineEfavirenz may increase the sedative activities of Rotigotine.Approved
RoxithromycinThe serum concentration of Roxithromycin can be decreased when it is combined with Efavirenz.Approved, Withdrawn
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Efavirenz.Approved
RuxolitinibThe serum concentration of Ruxolitinib can be decreased when it is combined with Efavirenz.Approved
S-EthylisothioureaThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Efavirenz.Experimental
Sage 547The risk or severity of adverse effects can be increased when Efavirenz is combined with Sage 547.Investigational
Salicylic acidThe metabolism of Salicylic acid can be decreased when combined with Efavirenz.Approved, Vet Approved
SalmeterolThe serum concentration of Salmeterol can be decreased when it is combined with Efavirenz.Approved
SaquinavirThe risk or severity of adverse effects can be increased when Saquinavir is combined with Efavirenz.Approved, Investigational
SaxagliptinThe serum concentration of Saxagliptin can be decreased when it is combined with Efavirenz.Approved
ScopolamineThe risk or severity of adverse effects can be increased when Efavirenz is combined with Scopolamine.Approved
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Efavirenz.Approved, Vet Approved
SelegilineThe serum concentration of Selegiline can be decreased when it is combined with Efavirenz.Approved, Investigational, Vet Approved
SelexipagThe serum concentration of Selexipag can be decreased when it is combined with Efavirenz.Approved
SeratrodastThe serum concentration of Seratrodast can be decreased when it is combined with Efavirenz.Approved, Investigational
SertindoleThe serum concentration of Sertindole can be decreased when it is combined with Efavirenz.Approved, Withdrawn
SertralineThe serum concentration of Sertraline can be decreased when it is combined with Efavirenz.Approved
SevofluraneThe serum concentration of Sevoflurane can be decreased when it is combined with Efavirenz.Approved, Vet Approved
SibutramineThe serum concentration of Sibutramine can be decreased when it is combined with Efavirenz.Approved, Illicit, Investigational, Withdrawn
SildenafilThe serum concentration of Sildenafil can be decreased when it is combined with Efavirenz.Approved, Investigational
SilodosinThe serum concentration of Silodosin can be decreased when it is combined with Efavirenz.Approved
SiltuximabThe serum concentration of Efavirenz can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Simeprevir can be decreased when it is combined with Efavirenz.Approved
SimvastatinThe serum concentration of Simvastatin can be decreased when it is combined with Efavirenz.Approved
SirolimusThe serum concentration of Sirolimus can be decreased when it is combined with Efavirenz.Approved, Investigational
SitagliptinThe serum concentration of Sitagliptin can be decreased when it is combined with Efavirenz.Approved, Investigational
SitaxentanThe metabolism of Sitaxentan can be decreased when combined with Efavirenz.Approved, Investigational, Withdrawn
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Efavirenz.Approved
SolifenacinThe serum concentration of Solifenacin can be decreased when it is combined with Efavirenz.Approved
SonidegibThe serum concentration of Sonidegib can be decreased when it is combined with Efavirenz.Approved, Investigational
SorafenibThe serum concentration of Sorafenib can be decreased when it is combined with Efavirenz.Approved, Investigational
SpiramycinThe serum concentration of Spiramycin can be decreased when it is combined with Efavirenz.Approved
St. John's WortThe serum concentration of Efavirenz can be decreased when it is combined with St. John's Wort.Nutraceutical
StiripentolThe serum concentration of Efavirenz can be increased when it is combined with Stiripentol.Approved
SufentanilThe serum concentration of Sufentanil can be decreased when it is combined with Efavirenz.Approved, Investigational
SulfadiazineThe serum concentration of Sulfadiazine can be decreased when it is combined with Efavirenz.Approved, Vet Approved
SulfamethoxazoleThe serum concentration of Sulfamethoxazole can be decreased when it is combined with Efavirenz.Approved
SulfamoxoleThe metabolism of Sulfamoxole can be decreased when combined with Efavirenz.Approved
SulfinpyrazoneThe serum concentration of Sulfinpyrazone can be decreased when it is combined with Efavirenz.Approved
SulfisoxazoleThe metabolism of Efavirenz can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Efavirenz.Approved
SunitinibThe serum concentration of Sunitinib can be decreased when it is combined with Efavirenz.Approved, Investigational
SuprofenThe metabolism of Suprofen can be decreased when combined with Efavirenz.Approved, Withdrawn
SuvorexantEfavirenz may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
Synthetic Conjugated Estrogens, AThe serum concentration of Synthetic Conjugated Estrogens, A can be decreased when it is combined with Efavirenz.Approved
Synthetic Conjugated Estrogens, BThe serum concentration of Synthetic Conjugated Estrogens, B can be decreased when it is combined with Efavirenz.Approved
TacrolimusThe serum concentration of Tacrolimus can be decreased when it is combined with Efavirenz.Approved, Investigational
TadalafilThe serum concentration of Tadalafil can be decreased when it is combined with Efavirenz.Approved, Investigational
TamoxifenThe serum concentration of Tamoxifen can be decreased when it is combined with Efavirenz.Approved
TamsulosinThe serum concentration of Tamsulosin can be decreased when it is combined with Efavirenz.Approved, Investigational
TandospironeThe risk or severity of adverse effects can be increased when Efavirenz is combined with Tandospirone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Efavirenz.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Efavirenz is combined with Tasimelteon.Approved
TasosartanThe serum concentration of Tasosartan can be decreased when it is combined with Efavirenz.Approved
Taurochenodeoxycholic acidThe serum concentration of Taurochenodeoxycholic acid can be decreased when it is combined with Efavirenz.Experimental
TazaroteneThe metabolism of Tazarotene can be decreased when combined with Efavirenz.Approved, Investigational
TelaprevirThe serum concentration of Telaprevir can be decreased when it is combined with Efavirenz.Approved
TelithromycinThe metabolism of Efavirenz can be decreased when combined with Telithromycin.Approved
TemazepamThe serum concentration of Temazepam can be decreased when it is combined with Efavirenz.Approved
TemsirolimusThe serum concentration of Temsirolimus can be decreased when it is combined with Efavirenz.Approved
TeniposideThe serum concentration of Teniposide can be decreased when it is combined with Efavirenz.Approved
TenoxicamThe metabolism of Tenoxicam can be decreased when combined with Efavirenz.Approved
TerbinafineThe serum concentration of Terbinafine can be decreased when it is combined with Efavirenz.Approved, Investigational, Vet Approved
TerfenadineThe serum concentration of Terfenadine can be decreased when it is combined with Efavirenz.Withdrawn
TesmilifeneThe serum concentration of Tesmilifene can be decreased when it is combined with Efavirenz.Investigational
TestosteroneThe serum concentration of Testosterone can be decreased when it is combined with Efavirenz.Approved, Investigational
TetrabenazineThe risk or severity of adverse effects can be increased when Efavirenz is combined with Tetrabenazine.Approved
TetracaineThe risk or severity of adverse effects can be increased when Tetracaine is combined with Efavirenz.Approved, Vet Approved
TetracyclineThe serum concentration of Tetracycline can be decreased when it is combined with Efavirenz.Approved, Vet Approved
TetrodotoxinThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Efavirenz.Investigational
ThalidomideEfavirenz may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
TheophyllineThe serum concentration of Theophylline can be decreased when it is combined with Efavirenz.Approved
ThiamylalThe risk or severity of adverse effects can be increased when Thiamylal is combined with Efavirenz.Approved, Vet Approved
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Efavirenz.Approved, Vet Approved
ThioridazineThe serum concentration of Thioridazine can be increased when it is combined with Efavirenz.Approved
ThiotepaThe serum concentration of Thiotepa can be decreased when it is combined with Efavirenz.Approved
ThiothixeneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Efavirenz.Approved
TiagabineThe serum concentration of Tiagabine can be decreased when it is combined with Efavirenz.Approved
TiaprideThe risk or severity of adverse effects can be increased when Efavirenz is combined with Tiapride.Investigational
TicagrelorThe serum concentration of Ticagrelor can be decreased when it is combined with Efavirenz.Approved
TiclopidineThe serum concentration of Ticlopidine can be decreased when it is combined with Efavirenz.Approved
TiletamineThe risk or severity of adverse effects can be increased when Tiletamine is combined with Efavirenz.Vet Approved
TimololThe metabolism of Timolol can be decreased when combined with Efavirenz.Approved
TinidazoleThe serum concentration of Tinidazole can be decreased when it is combined with Efavirenz.Approved, Investigational
TiotropiumThe serum concentration of Tiotropium can be decreased when it is combined with Efavirenz.Approved
TipranavirThe serum concentration of Tipranavir can be decreased when it is combined with Efavirenz.Approved, Investigational
TizanidineThe risk or severity of adverse effects can be increased when Efavirenz is combined with Tizanidine.Approved
TocilizumabThe serum concentration of Efavirenz can be decreased when it is combined with Tocilizumab.Approved
TofacitinibThe serum concentration of Tofacitinib can be decreased when it is combined with Efavirenz.Approved, Investigational
TolbutamideThe metabolism of Tolbutamide can be decreased when combined with Efavirenz.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Efavirenz.Approved, Withdrawn
Tolfenamic AcidThe serum concentration of Tolfenamic Acid can be decreased when it is combined with Efavirenz.Approved
TolterodineThe serum concentration of Tolterodine can be decreased when it is combined with Efavirenz.Approved, Investigational
TolvaptanThe serum concentration of Tolvaptan can be decreased when it is combined with Efavirenz.Approved
TopiramateThe risk or severity of adverse effects can be increased when Topiramate is combined with Efavirenz.Approved
TorasemideThe metabolism of Torasemide can be decreased when combined with Efavirenz.Approved
ToremifeneThe serum concentration of Toremifene can be decreased when it is combined with Efavirenz.Approved, Investigational
TrabectedinThe serum concentration of Trabectedin can be decreased when it is combined with Efavirenz.Approved, Investigational
TramadolThe serum concentration of Tramadol can be decreased when it is combined with Efavirenz.Approved, Investigational
TranilastThe serum concentration of Tranilast can be decreased when it is combined with Efavirenz.Approved, Investigational
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Efavirenz.Experimental
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Efavirenz.Approved
Trastuzumab emtansineThe serum concentration of Trastuzumab emtansine can be decreased when it is combined with Efavirenz.Approved
TrazodoneThe serum concentration of Trazodone can be decreased when it is combined with Efavirenz.Approved, Investigational
TreprostinilThe metabolism of Treprostinil can be decreased when combined with Efavirenz.Approved, Investigational
TretinoinThe serum concentration of Tretinoin can be decreased when it is combined with Efavirenz.Approved, Investigational, Nutraceutical
TriamcinoloneThe serum concentration of Triamcinolone can be decreased when it is combined with Efavirenz.Approved, Vet Approved
TriazolamThe serum concentration of Triazolam can be decreased when it is combined with Efavirenz.Approved
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Efavirenz.Approved
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Efavirenz.Approved, Vet Approved
TrimethadioneThe serum concentration of Trimethadione can be decreased when it is combined with Efavirenz.Approved
TrimethoprimThe serum concentration of Trimethoprim can be decreased when it is combined with Efavirenz.Approved, Vet Approved
TrimipramineThe serum concentration of Trimipramine can be decreased when it is combined with Efavirenz.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Triprolidine is combined with Efavirenz.Approved
TroglitazoneThe serum concentration of Troglitazone can be decreased when it is combined with Efavirenz.Withdrawn
TroleandomycinThe serum concentration of Troleandomycin can be decreased when it is combined with Efavirenz.Approved
Uc1010The risk or severity of adverse effects can be increased when Efavirenz is combined with Uc1010.Investigational
UdenafilThe serum concentration of Udenafil can be decreased when it is combined with Efavirenz.Approved, Investigational
UlipristalThe serum concentration of Ulipristal can be decreased when it is combined with Efavirenz.Approved
ValdecoxibThe serum concentration of Valdecoxib can be decreased when it is combined with Efavirenz.Investigational, Withdrawn
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Efavirenz.Approved, Investigational
ValsartanThe metabolism of Valsartan can be decreased when combined with Efavirenz.Approved, Investigational
VandetanibThe serum concentration of Vandetanib can be decreased when it is combined with Efavirenz.Approved
VanoxerineThe serum concentration of Vanoxerine can be decreased when it is combined with Efavirenz.Investigational
VardenafilThe serum concentration of Vardenafil can be decreased when it is combined with Efavirenz.Approved
VemurafenibThe serum concentration of Vemurafenib can be decreased when it is combined with Efavirenz.Approved
VenetoclaxThe serum concentration of Venetoclax can be decreased when it is combined with Efavirenz.Approved
VenlafaxineThe serum concentration of Venlafaxine can be decreased when it is combined with Efavirenz.Approved
VerapamilThe serum concentration of Verapamil can be decreased when it is combined with Efavirenz.Approved
VicrivirocThe serum concentration of Vicriviroc can be decreased when it is combined with Efavirenz.Investigational
VigabatrinThe risk or severity of adverse effects can be increased when Efavirenz is combined with Vigabatrin.Approved
VilanterolThe serum concentration of Vilanterol can be decreased when it is combined with Efavirenz.Approved
VilazodoneThe serum concentration of Vilazodone can be decreased when it is combined with Efavirenz.Approved
VinblastineThe serum concentration of Vinblastine can be decreased when it is combined with Efavirenz.Approved
VincristineThe serum concentration of Vincristine can be decreased when it is combined with Efavirenz.Approved, Investigational
VindesineThe serum concentration of Vindesine can be decreased when it is combined with Efavirenz.Approved
VinorelbineThe serum concentration of Vinorelbine can be decreased when it is combined with Efavirenz.Approved, Investigational
VinpocetineThe serum concentration of Vinpocetine can be decreased when it is combined with Efavirenz.Investigational
VismodegibThe serum concentration of Vismodegib can be decreased when it is combined with Efavirenz.Approved
VoriconazoleThe serum concentration of Voriconazole can be decreased when it is combined with Efavirenz.Approved, Investigational
VortioxetineThe serum concentration of Vortioxetine can be decreased when it is combined with Efavirenz.Approved
WarfarinThe serum concentration of Warfarin can be decreased when it is combined with Efavirenz.Approved
XimelagatranThe metabolism of Ximelagatran can be decreased when combined with Efavirenz.Approved, Investigational, Withdrawn
XylazineThe risk or severity of adverse effects can be increased when Xylazine is combined with Efavirenz.Vet Approved
XylometazolineThe serum concentration of Xylometazoline can be decreased when it is combined with Efavirenz.Approved
YohimbineThe serum concentration of Yohimbine can be decreased when it is combined with Efavirenz.Approved, Vet Approved
ZafirlukastThe serum concentration of Zafirlukast can be decreased when it is combined with Efavirenz.Approved, Investigational
ZalcitabineThe serum concentration of Zalcitabine can be decreased when it is combined with Efavirenz.Approved
ZaleplonThe serum concentration of Zaleplon can be decreased when it is combined with Efavirenz.Approved, Illicit, Investigational
ZaltoprofenThe metabolism of Zaltoprofen can be decreased when combined with Efavirenz.Approved
ZiconotideThe serum concentration of Ziconotide can be decreased when it is combined with Efavirenz.Approved
ZidovudineThe serum concentration of Zidovudine can be decreased when it is combined with Efavirenz.Approved
ZileutonThe serum concentration of Zileuton can be decreased when it is combined with Efavirenz.Approved, Investigational, Withdrawn
ZimelidineThe risk or severity of adverse effects can be increased when Efavirenz is combined with Zimelidine.Withdrawn
ZiprasidoneThe serum concentration of Ziprasidone can be decreased when it is combined with Efavirenz.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Zolazepam is combined with Efavirenz.Vet Approved
ZolpidemEfavirenz may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZomepiracThe serum concentration of Zomepirac can be decreased when it is combined with Efavirenz.Withdrawn
ZonisamideThe serum concentration of Zonisamide can be decreased when it is combined with Efavirenz.Approved, Investigational
ZopicloneThe serum concentration of Zopiclone can be decreased when it is combined with Efavirenz.Approved
ZotepineThe risk or severity of adverse effects can be increased when Zotepine is combined with Efavirenz.Approved
ZuclopenthixolThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Efavirenz.Approved, Investigational
Food Interactions
  • Avoid excessive or chronic alcohol consumption.
  • Take without regard to meals.
References
Synthesis Reference

John Doney, “Amorphous efavirenz and the production thereof.” U.S. Patent US20070026073, issued February 01, 2007.

US20070026073
General References
  1. Ren J, Bird LE, Chamberlain PP, Stewart-Jones GB, Stuart DI, Stammers DK: Structure of HIV-2 reverse transcriptase at 2.35-A resolution and the mechanism of resistance to non-nucleoside inhibitors. Proc Natl Acad Sci U S A. 2002 Oct 29;99(22):14410-5. Epub 2002 Oct 17. [PubMed:12386343 ]
External Links
ATC CodesJ05AR06J05AG03J05AR11
AHFS Codes
  • 08:18.08.16
PDB EntriesNot Available
FDA labelDownload (154 KB)
MSDSDownload (57.6 KB)
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9964
Blood Brain Barrier+0.9182
Caco-2 permeable+0.5553
P-glycoprotein substrateNon-substrate0.7617
P-glycoprotein inhibitor INon-inhibitor0.7451
P-glycoprotein inhibitor IINon-inhibitor0.9557
Renal organic cation transporterNon-inhibitor0.9157
CYP450 2C9 substrateNon-substrate0.8033
CYP450 2D6 substrateNon-substrate0.9116
CYP450 3A4 substrateSubstrate0.6037
CYP450 1A2 substrateInhibitor0.6996
CYP450 2C9 inhibitorNon-inhibitor0.6975
CYP450 2D6 inhibitorNon-inhibitor0.8699
CYP450 2C19 inhibitorNon-inhibitor0.5291
CYP450 3A4 inhibitorNon-inhibitor0.7577
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.6705
Ames testNon AMES toxic0.6991
CarcinogenicityNon-carcinogens0.8997
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.5416 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9617
hERG inhibition (predictor II)Non-inhibitor0.9098
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Bristol myers squibb co
  • Bristol myers squibb pharma co
Packagers
Dosage forms
FormRouteStrength
TabletOral
Tablet, film coatedOral
SolutionOral30 mg/ml
Tablet, film coatedOral200 mg
Tablet, film coatedOral50 mg
Tablet, film coatedOral600 mg
Capsule, gelatin coatedOral200 mg/1
Capsule, gelatin coatedOral50 mg/1
Tablet, film coatedOral600 mg/1
CapsuleOral100 mg
CapsuleOral200 mg
CapsuleOral50 mg
TabletOral600 mg
Prices
Unit descriptionCostUnit
Sustiva 600 mg tablet21.68USD tablet
Sustiva 200 mg capsule7.37USD capsule
Sustiva 100 mg capsule3.34USD capsule
Sustiva 50 mg capsule1.84USD capsule
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA2101572 No2001-08-282013-07-29Canada
CA2279198 No2009-04-142018-02-02Canada
US5811423 No1992-08-072012-08-07Us
US5814639 Yes1996-03-292016-03-29Us
US5914331 Yes1998-01-022018-01-02Us
US5922695 Yes1998-01-252018-01-25Us
US5935946 Yes1998-01-252018-01-25Us
US5977089 Yes1998-01-252018-01-25Us
US6043230 Yes1998-01-252018-01-25Us
US6238695 Yes1999-10-062019-10-06Us
US6555133 Yes1999-10-062019-10-06Us
US6639071 Yes1998-08-142018-08-14Us
US6642245 Yes2001-05-042021-05-04Us
US6703396 Yes2001-09-092021-09-09Us
US6939964 Yes1998-07-202018-07-20Us
US8592397 No2004-01-132024-01-13Us
US8598185 No2008-05-012028-05-01Us
US8716264 No2004-01-132024-01-13Us
US9018192 No2006-06-132026-06-13Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point139-141 °CNot Available
logP4.6Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.00855 mg/mLALOGPS
logP3.89ALOGPS
logP4.46ChemAxon
logS-4.6ALOGPS
pKa (Strongest Acidic)12.52ChemAxon
pKa (Strongest Basic)-1.5ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area38.33 Å2ChemAxon
Rotatable Bond Count3ChemAxon
Refractivity71.34 m3·mol-1ChemAxon
Polarizability26.81 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as benzoxazines. These are organic compounds containing a benzene fused to an oxazine ring (a six-membered aliphatic ring with four carbon atoms, one oxygen atom, and one nitrogen atom).
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassBenzoxazines
Sub ClassNot Available
Direct ParentBenzoxazines
Alternative Parents
Substituents
  • Benzoxazine
  • Benzenoid
  • Ynone
  • Aryl halide
  • Aryl chloride
  • Oxacycle
  • Azacycle
  • Monocarboxylic acid or derivatives
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Organofluoride
  • Organochloride
  • Organohalogen compound
  • Alkyl halide
  • Alkyl fluoride
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptors

Targets

Kind
Protein
Organism
Human immunodeficiency virus 1
Pharmacological action
yes
Actions
inhibitor
General Function:
Rna-dna hybrid ribonuclease activity
Specific Function:
Not Available
Gene Name:
pol
Uniprot ID:
Q72547
Molecular Weight:
65223.615 Da
References
  1. Gazzard BG: Efavirenz in the management of HIV infection. Int J Clin Pract. 1999 Jan-Feb;53(1):60-4. [PubMed:10344069 ]
  2. Adkins JC, Noble S: Efavirenz. Drugs. 1998 Dec;56(6):1055-64; discussion 1065-6. [PubMed:9878993 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitorinducer
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Acts as a 1,4-cineole 2-exo-monooxygenase.
Gene Name:
CYP2B6
Uniprot ID:
P20813
Molecular Weight:
56277.81 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  2. Hesse LM, von Moltke LL, Shader RI, Greenblatt DJ: Ritonavir, efavirenz, and nelfinavir inhibit CYP2B6 activity in vitro: potential drug interactions with bupropion. Drug Metab Dispos. 2001 Feb;29(2):100-2. [PubMed:11159797 ]
  3. Walsky RL, Astuccio AV, Obach RS: Evaluation of 227 drugs for in vitro inhibition of cytochrome P450 2B6. J Clin Pharmacol. 2006 Dec;46(12):1426-38. [PubMed:17101742 ]
  4. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  5. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitorinducer
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and imipramine.
Gene Name:
CYP2C19
Uniprot ID:
P33261
Molecular Weight:
55930.545 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenyto...
Gene Name:
CYP2C9
Uniprot ID:
P11712
Molecular Weight:
55627.365 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Most active in catalyzing 2-hydroxylation. Caffeine is metabolized primarily by cytochrome CYP1A2 in the liver through an initial N...
Gene Name:
CYP1A2
Uniprot ID:
P05177
Molecular Weight:
58293.76 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on December 07, 2016 03:54